Stock Ratings / Health Care / TLPH / dividends

CLNN (34) HRTX (37) ONCY (45) HYPD (50) ⌘ Pro Terminal →

Talphera Inc. (TLPH) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.03 -3.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.02

Talphera Inc. (TLPH) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $55.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TLPH Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TLPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Talphera Inc. (NASDAQ: TLPH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.03 (-3.74% 1D, market cap $55.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TLPH ranks #482 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TLPH compare to CLNN and HRTX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TLPH carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLNN (Clene Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $55.4M) and HRTX (Heron Therapeutics Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $55.9M). Among the 5-stock peer group, TLPH leads on earnings multiple (N/A) while TLPH leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TLPH?

▼

Per TLPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001427925), Talphera Inc. generated $0 in revenue, -$14.3M in net income, and -$11.4M in free cash flow against $29.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.02 (-0.86%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TLPH)Realized 20D OHLCV Swing Band: ±8.7%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY TLPH SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (29% of score)

FRED Regime × Technicals: 39% of 52W Range • RSI-14 at 34.6 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.08+0% Next Q

Q2 (-2Q)

Grade D$1.08+0% Next Q

Q3 (-1Q)

Grade D$1.08-4.6% Next Q

Current

Grade D-$1.03-7% Hist 90D α

Trajectory: C- (50) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TLPH Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TLPH currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.15) and Max Pain ($1.08) forces dealer call-delta covering toward $1.65.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TLPH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TLPH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TLPH)

✓Walkthrough of TLPH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TLPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +13.19%⚡ TESTING RESISTANCE

2026-10-30O $1.07H $1.08L $1.03C $1.03VOL 82.5K

RES: $1.09SUP: $1.00SMA50: $1.15SMA200: $1.01

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TLPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TLPH Butterfly Map → + Track TLPH →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TLPH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TLPH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TLPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TLPH)

Health Care Rank #482 of 1016 ⚔️ CLNN vs TLPH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TLPH vs. CLNN, HRTX, ONCY, HYPD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Talphera Inc. (TLPH) ranks #482 by composite RQD confidence (42/100, grade D-) and #734 by equity capitalization ($55.5M). Within this direct 5-issuer industry benchmark cohort, TLPH leads on earnings valuation at N/A trailing P/E, while TLPH leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. HYPD currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with TLPH at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TLPH ACTIVE Talphera Inc.	D-	42/100	—	—	-35.0%	-3.74%	$55.5M	Benchmark Subject
CLNN Clene Inc.	E	34/100	—	78.5%	-35.0%	-1.79%	$55.4M	/clnn-vs-tlph →
HRTX Heron Therapeutics Inc.	D-	37/100	—	73.3%	-35.0%	-5.67%	$55.9M	/hrtx-vs-tlph →
ONCY Oncolytics Biotech Inc.	D	45/100	—	—	-35.0%	-0.54%	$56.1M	/oncy-vs-tlph →
HYPD Hyperion DeFi Inc.	D	50/100	—	62.7%	-35.0%	-8.13%	$54.1M	/hypd-vs-tlph →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001427925

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Talphera Inc. (TLPH) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$14.3M, operating cash flow of -$11.4M, and free cash flow of -$11.4M (+10.4% YoY). On the balance sheet, TLPH closed FY2025 with $29.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$14.3M	-$11.4M	-$11.4M	$29.7M	—
FY2024 (FY)	2024-12-31	$0	-$13.0M	-$12.7M	-$12.7M	$18.2M	—
FY2023 (FY)	2023-12-31	$0	-$18.4M	-$17.5M	-$17.5M	—	—

3. TLPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TLPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does TLPH compare to CLNN and HRTX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for TLPH?

Where is TLPH trading relative to its 50-day, 200-day, and 52-week technical levels?

TLPH last traded at $1.03 (-3.74% on volume of 83,509 shares), positioning the stock -10.43% below its 50-day simple moving average ($1.15) and +1.98% above its 200-day simple moving average ($1.01). Across its 52-week range of $0.69 to $1.57, TLPH sits at the 38.6% percentile with a 14-day RSI of 34.6 (NEUTRAL RANGE) and an implied next-earnings move of ±8.7% ($1.00 to $1.12).

TLPH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does TLPH pay a dividend and is it safe?

Talphera Inc. (TLPH) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: TLPH RQD Cockpit TLPH 12M Forecast TLPH Earnings & Move TLPH Dividends & DRIP TLPH Insiders & 13F TLPH Whale Options TLPH Profit Sankey TLPH News & Why